Category - Markets

BTIG initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and price target of $5.50. The stock closed at $2.96 on Feb. 12. “MEI Pharma is developing in-licensed drugs that we see as having good chances of...

Stifel initiated coverage of Ra Pharmaceuticals (NASDAQ:RARX) with a “buy” rating and $55 price target. The stock closed at $19.87 on Feb. 7. Ra Pharma uses a proprietary peptide chemistry platform to develop...

SVB Leerink downgraded Solid Biosciences (NASDAQ:SLDB) to “market perform” from “outperform” and slashed its price target to $8 from $50 after the company reported disappointing Phase 1/2 data from its experimental gene...

Dawson James Securities initiated coverage of BioTime (NYSE American:BTX) with a “buy” rating and $6 price target. The stock closed at $1.16 on Feb. 6. “We view BioTime as a new company invigorated by a new management...

SVB Leerink launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with an “outperform” rating and sum-of-the-parts price target of $10. The stock closed at $3.66 on Feb. 5. Analyst Marc Goodman writes that his...

H.C. Wainwright raised its price target for Trevena (NASDAQ:TRVN) to $1.25 from 75 cents, saying that resolution on two clinical requests from the FDA paves a path for the company’s NDA resubmission for oliceridine, a...

H.C. Wainwright lowered its price target for Rexahn Pharmaceuticals (NYSE American:PNN) to $10 from $17 to reflect a higher number of shares outstanding after an equity issue in January. The stock closed at 63 cents on...

Analyst at Leerink and H.C. Wainwright lowered their price targets for AC Immune (NASDAQ:ACIU) after the company’s partner, Roche/Genentech, discontinued the Phase 3 CREAD 1 and 2 trials of crenezumab for the treatment...

H.C. Wainwright downgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “neutral” from “buy” and slashed its price target to $1 from $9 after the FDA recommended against the filing of a tivozanib NDA, citing the lack of...

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast (NASDAQ:MESO) with a “buy” rating and price target of $6.50. The stock closed at $4.56 on Jan. 30. Australia-based Mesoblast is focused on...